Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
1992-9-3
|
pubmed:abstractText |
We recently reported that estrogen exerts distinct effects on the GH/IGF-1 axis that are dependent on the route of delivery, probably reflecting a first-pass effect on hepatic IGF-1 production. Oral administration reduces IGF-1 and increases GH levels; transdermal administration elevates IGF-1 without changing GH concentrations. Since mesenchymal tissue is a target for GH and IGF-1 action, we studied changes in the GH/IGF-1 axis following oral (ethinyl estradiol, 20 micrograms/day) versus transdermal (Estraderm 100 TTS, Ciba Geigy, 100 micrograms 17 beta-estradiol per day) estrogen delivery and compared corresponding effects on connective and bone tissue metabolism. Mean 24 h GH levels, IGF-1, markers of fibroblast (procollagen III) and osteoblast (procollagen I, osteocalcin) function, and indices of bone turnover (fasting urinary hydroxyproline and calcium to creatinine ratios, UOHPr/Cr and UCa/Cr) were measured before and after 2 months of either oral or transdermal therapy in two groups of postmenopausal women. Transdermal estrogen administration significantly (p less than 0.05) increased IGF-1, procollagen III, procollagen I, osteocalcin, and UOHPr/Cr. In contrast, oral estrogen administration had a suppressive effect; the levels of IGF-1 (p = 0.001), procollagen III (p = 0.018), procollagen I (p = 0.002), osteocalcin (p = 0.015), and UOHPr/Cr (p = 0.004) were significantly different from those measured during transdermal administration. Both treatments significantly reduced UCa/Cr (p less than 0.015). IGF-1 changes during estrogen therapy were significantly related (p less than 0.05) to changes in procollagen III, procollagen I, osteocalcin, and UOHPr/Cr. Transdermally delivered estrogen stimulates IGF-1 production, increases osteoblastic function, and stimulates bone and nonbone collagen synthesis.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Ethinyl Estradiol,
http://linkedlifedata.com/resource/pubmed/chemical/Follicle Stimulating Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Luteinizing Hormone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0884-0431
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
821-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1642149-Administration, Cutaneous,
pubmed-meshheading:1642149-Administration, Oral,
pubmed-meshheading:1642149-Bone and Bones,
pubmed-meshheading:1642149-Collagen,
pubmed-meshheading:1642149-Connective Tissue,
pubmed-meshheading:1642149-Estradiol,
pubmed-meshheading:1642149-Ethinyl Estradiol,
pubmed-meshheading:1642149-Female,
pubmed-meshheading:1642149-Fibroblasts,
pubmed-meshheading:1642149-Follicle Stimulating Hormone,
pubmed-meshheading:1642149-Growth Hormone,
pubmed-meshheading:1642149-Humans,
pubmed-meshheading:1642149-Insulin-Like Growth Factor I,
pubmed-meshheading:1642149-Luteinizing Hormone,
pubmed-meshheading:1642149-Middle Aged,
pubmed-meshheading:1642149-Osteoblasts
|
pubmed:year |
1992
|
pubmed:articleTitle |
Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism.
|
pubmed:affiliation |
Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|